{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a palmitate
to a specific field?
Status:
Investigational
Source:
NCT00666926: Phase 1 Interventional Completed Head and Neck Neoplasm
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04142749: Phase 3 Interventional Completed Non-Alcoholic Fatty Liver Disease
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Oltipraz is an organosulfur compound belonging to the dithiolethione class. It acts as a schistosomicide and has been shown in rodent models to inhibit the formation of cancers in the bladder, blood, colon, kidney, liver, lung, pancreas, stomach, and trachea, skin, and mammary tissue. Oltipraz and other 1,2-dithiole-3-thiones inactivate protein tyrosine phosphatases under physiologically-relevant conditions. Clinical trials of oltipraz have failed to demonstrate efficacy and have shown significant side effects, including neurotoxicity and gastrointestinal toxicity.
Class (Stereo):
CHEMICAL (MIXED)
Spiroxepin is a dioxolane derivative patented by Delalande S. A. as an antidepressant and spasmolytic agent.
Status:
Investigational
Source:
NCT00336544: Phase 3 Interventional Completed Pneumonia
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cethromycin is a ketolide antibiotic derived from erythromycin A being investigated for use in community-acquired pneumonia and other respiratory tract infections. Cethromycin possesses reliable activity against the bacteria most commonly associated with community-acquired pneumonia including S. pneumoniae, H. influenzae, M. catarrhalis, M. pneumoniae, C. pneumoniae, and L. pneumophila. Unlike fluoroquinolones, cethromycin has a narrower spectrum of activity against gram-negative bacteria, which may reduce the risk of collateral damage and the incidence of Clostridium difficile infection. It offers an advantage over telithromycin in that hepatotoxicity does not seem to be a concern. The FDA denied approval of cethromycin for the treatment of CAP in 2009, requesting more efficacy data.
Status:
Investigational
Source:
NCT00389779: Phase 3 Interventional Completed Hypertension
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Darusentan is an orally active, propanoic acid-based endothelin receptor antagonist (ERA) that selectively blocks endothelin-1 (ET-1) binding to the endothelin type-A (ETA) receptor. Darusentan exhibited subnanomolar binding affinity and approximately 1000-fold selectivity for the ETA receptor in binding experiments conducted in vitro under steady-state conditions. Darusentan is orally bioavailable and, when administered to humans, maximum plasma concentrations are observed within 1–2 h post dosing. The mean elimination half-life is relatively long (>15 h), which is consistent with once-daily dosing. Darusentan is primarily glucuronidated by Phase II enzymes in the liver, and the major route of elimination of Darusentan and its metabolites is via the bile. Some glucuronidated metabolites of Darusentan are also excreted in the urine. Darusentan doses up to 300 mg/day were well tolerated and associated with a manageable safety profile in patients with resistant hypertension (RHTN). The most frequently reported adverse events in Ddarusentan-treated subjects were peripheral edema (17%) and headache (11%), which were mostly mild or moderate in severity. Other commonly reported adverse events in the Darusentan treatment group were sinusitis (8%), dizziness (7%), upper respiratory tract infection (5%) and gastroenteritis (5%). In phase III clinical trial the mean reductions in clinic systolic and diastolic blood pressures were 9/5 mm Hg with placebo, 17/10 mm Hg with Darusentan 50 mg, 18/10 mm Hg with Darusentan 100 mg, and 18/11 mm Hg with Darusentan 300 mg. Unfortunately, phase III clinical trial evaluating Darusentan did not achieve its co-primary efficacy endpoints of achieving a change in systolic and diastolic blood pressure after 14 weeks compared to a placebo. Perhaps for this reason, shortly after the top-line results of this study became known, the sponsor announced that Darusentan would not be developed further for resistant hypertension.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulfaproxyline is a sulfonamide derivative patented by J. R. Geigy A.-G. as an antibiotic, useful in the treatment of urinary tract infections. In preclinical models, sulfaproxyline is effective against staphylococci infection in guinea pigs. Bisulfon D, a drug product comprising the combination of sulfaproxyline and sulfamerazine has been used for the treatment of urinary tract infections in the puerperium.
Status:
Investigational
Source:
INN:sulocarbilate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sulocarbilate (also known as W-1548-1) is a sulfanilamide derivative and carbonic anhydrase inhibitor with diuretic activity. In preclinical models, Sulocarbilate shows similar efficacy and superior safety profile compared to other agents of this type. Clinically, Sulocarbilate shows the maximum effect as a natriuretic agent in an oral daily dose of 2 g.
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulosemide is a sulfamoylorthanilic acid derivative patented by German chemicals then life-sciences company Hoechst A.-G. as salidiuretic agent.
Status:
Investigational
Source:
INN:terflavoxate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Terflavoxate is a benzopyran derivative patented by Recordati S. A. Chemical and Pharmaceutical Co. as a muscle relaxant, anesthetic, anti-inflammatory, and antispastic agent useful for the treatment of lower urinary tract disease. Terflavoxate inhibited by more than 50% field stimulation-induced contractions of rabbit bladder strips, indicates that mechanisms other than the anticholinergic one should be responsible for its smooth muscle relaxant properties.
